Meeting
2022 ASCO Annual Meeting
Evaluation of booster injections in maintaining peak immunity in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus GM-CSF alone after adjuvant trastuzumab in women with HER2-positive breast cancer.
Authors
Snehal Patel
Greenwich LifeSciences, Stafford, TX
Snehal Patel , David McWilliams , Jaye Thompson , Mira Patel , F. Joseph Daugherty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
00524277
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA550)
DOI
10.1200/JCO.2022.40.17_suppl.LBA550
Abstract #
LBA550
Poster Bd #
322
Abstract Disclosures
Similar Posters
First Author: Snehal Patel
Poster
2022 ASCO Annual Meeting
A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.
First Author: Snehal Patel
Poster
2021 ASCO Annual Meeting
A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.
First Author: Snehal Patel
Poster
2019 ASCO Annual Meeting
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.
First Author: Jessica Campf